Ultra-Hypofractionated Prostate Radiotherapy With Online Adaptive Technique: A Case Report

被引:2
|
作者
Yoganathan, S. A. [1 ]
Riyas, Mohamed [1 ]
Sukumaran, Renilmon [1 ]
Hammoud, Rabih [1 ]
Al-Hammadi, Noora [1 ]
机构
[1] Hamad Med Corp, Radiat Oncol, Doha, Qatar
关键词
cyberknife; ethos; adaptive; online; ultra-hypofractionated; prostate; CANCER;
D O I
10.7759/cureus.64101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ultra-hypofractionated radiotherapy (UHF RT) is revolutionizing the treatment approach for low- and intermediate-risk prostate cancer patients. This study reports the planning process of UHF RT utilizing the cone beam computed tomography (CBCT)-based online adaptive radiotherapy (OART) treatment with the Ethos system, focusing on a comparative analysis between OART and image-guided radiotherapy (IGRT) plans. We also assessed the pre-planning capabilities of the Ethos system against the CyberKnife (CK) (Accuray, Sunnyvale, CA) system. A 66-year-old patient, diagnosed with prostatic acinar adenocarcinoma confirmed via biopsy and presenting with elevated prostate-specific antigen (PSA) levels, underwent UHF OART treatment using the Ethos system. The planning encompassed delineating the gross target volume (GTV) as the prostate, while the clinical target volume (CTV) comprised the prostate and proximal seminal vesicle. The planning target volume (PTV) was derived from the CTV with a 5 mm external margin except for a 3 mm posterior margin. A simultaneous integrated boost (SIB) technique was employed, delivering 40 Gy in five fractions (8 Gy per fraction) to the gross tumor volume (GTV) and 36.25 Gy in five fractions (7.25 Gy per fraction) to the remaining part of the planning target volume (PTV), with treatments scheduled biweekly. We compared OART and IGRT plans and conducted a comparative analysis between Ethos planning and the CK system for pre-planning assessment. When comparing Ethos planning and CK plans, Ethos demonstrated slightly better target coverage and organ-at-risk (OAR) sparing. However, CK plans showed superior containment of low-dose spillage, particularly at 50% and 25% iso-doses, due to non-coplanar beam arrangements. Our results demonstrated that OART plans yielded superior target coverage and improved OAR sparing compared to IGRT plans. Notably, the entire OART process, from planning to delivery, was accomplished within 27 minutes. The Ethos OART system's ability to adapt to daily anatomical changes, efficient workflow, and superior OAR-sparing capabilities make it a promising option for prostate cancer treatment using UHF RT.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Toxicity, Dosimetric & Survival analysis of Ultra-Hypofractionated Radiotherapy for Breast Cancer
    Dandekar, Prasad Raj
    Gupte, Ajinkya
    Kadam, Rohan
    Kakade, Amol
    Dhoundiyal, Mayank
    Shaikh, Naseem
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S714 - S716
  • [22] Implementation of ultra-hypofractionated radiotherapy in early breast cancer: economic impact
    Mateu Castell, Luis
    Gadea Quinteiro, Jon
    Garcia Zanoguera, Carlos
    Curbelo Artiles, Alba G.
    Grau Morenilla, Andrea
    Llabres Busch, Gemma V.
    Ortiz Gonzalez, Irene
    Mestre Meste, Francisco J.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2839 - S2841
  • [23] Ultra-hypofractionated radiotherapy for breast cancer : Dosecontraints on the controlateral breast are warranted
    Ben Rejeb, M.
    Abdessattar, G.
    Ghorbel, S.
    Mezghani, M.
    Ghorbal, L.
    Kochbati, L.
    BREAST, 2025, 80
  • [24] Daily Online Adaptive Radiotherapy with Narrow Margins for Ultra-Hypofractionated Whole Breast Irradiation (A-FF-WBI): Dosimetry and Early Clinical Outcomes
    Li, X.
    Parsons, D. D. M.
    Visak, J.
    Arbab, M.
    Chen, L.
    Lu, W.
    Liao, C. Y.
    Tye, C.
    Bahrami, S.
    Wandrey, N.
    Alluri, P. G.
    Lin, M. H.
    Rahimi, A. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E320 - E320
  • [25] Ultra-hypofractionated SBRT for localized prostate cancer: single institution experience
    Acosta Rojas, A.
    Montero Luis, A.
    Valero Albarran, J.
    Hernando Requejo, O.
    Sanchez Saugar, E.
    Ciervide Jurio, R.
    Garcia-Aranda, M.
    Chen, X.
    Alonso Gutierrez, R.
    De la Casa, M. A.
    Zucca, D.
    Fernandez Leton, P.
    Rubio Rodriguez, M. C.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S619 - S620
  • [26] MACHINE LEARNING-BASED MODELS OF RADIO-INDUCED TOXICITY IN PROSTATE CANCER ULTRA-HYPOFRACTIONATED RADIOTHERAPY
    Zaffaroni, Mattia
    Pepa, Matteo
    Volpe, Stefania
    Marvaso, Giulia
    Isaksson, Johannes Lars
    Barzaghi, Simona
    Benigni, Federica
    Callegari, Marta
    Gismundi, Alessia
    La Fauci, Francesco
    Corrao, Giulia
    Augugliaro, Matteo
    Cattani, Federica
    Baroni, Guido
    De Momi, Elena
    Orecchia, Roberto
    Jereczek-Fossa, Barbara Alicja
    ANTICANCER RESEARCH, 2021, 41 (10) : 5287 - 5289
  • [27] Dosimetric comparison of conventionally and ultra-hypofractionated RT boost in prostate cancer
    Krawczyk, J.
    Ginter, A.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1676 - S1676
  • [28] Quantitative Relaxometry for Target Localization and Response Assessment in Ultra-Hypofractionated MR-Guided Radiotherapy to the Prostate and DIL
    Subashi, E.
    LoCastro, E.
    Apte, A.
    Zelefsky, M. J.
    Tyagi, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S33 - S33
  • [29] Acute toxicity patterns and their management after moderate and ultra-hypofractionated radiotherapy for prostate cancer: A prospective cohort study
    Sinzabakira, F.
    Incrocci, L.
    de Vries, K.
    Christianen, M. E. M. C.
    Franckena, M.
    Froklage, F. E.
    Westerveld, H.
    Heemsbergen, W. D.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 48
  • [30] “Give me five” ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach
    Giulia Marvaso
    Giulia Riva
    Delia Ciardo
    Sara Gandini
    Cristiana Fodor
    Dario Zerini
    Sarah Pia Colangione
    Giorgia Timon
    Stefania Comi
    Raffaella Cambria
    Federica Cattani
    Ottavio De Cobelli
    Roberto Orecchia
    Barbara A. Jereczek-Fossa
    Medical Oncology, 2018, 35